Novel Med Shows Early, Lasting Gains in Resistant Epilepsy

Novel Med Shows Early, Lasting Gains in Resistant Epilepsy

A novel, once-daily antiseizure medication (ASM) significantly reduced focal seizures in adults with drug-resistant epilepsy, with the higher dose showing benefit within the first week of treatment.Results of a phase 3 randomized, placebo-controlled trial showed that azetukalner, an investigational agent that opens Kv7 potassium channels, reduced monthly seizures by a median of 53.2% at 25 mg and 34.5% at 15 mg, compared with 10.4% with placebo.The trial “demonstrated that azetukalner demonstrated robust, rapid, and durable reductions in seizure frequency with a favorable risk-benefit profile,” the investigators, led by Jacqueline French, MD, an epileptologist at NYU Grossman School of Medicine and NYU Langone Health in New York City, wrote. The researchers also noted that the drug produced one of the largest median percentage reductions in seizure frequency vs placebo reported to date in this patient population. Further, they suggested that it could be a “promising novel antiseizure medication with significant opportunity to improve clinical outcomes.” The findings were published online November 9 in JAMA Neurology.Kv7 Drug Class Gets a Second ChanceMore than 50 million individuals worldwide have epilepsy, and more than half don’t achieve long-term seizure freedom with their first ASM, the researchers noted. Despite the availability of more than 30 ASMs, many patients continue to experience seizures, underscoring the need for treatments with novel mechanisms of action, they added.Unlike many existing ASMs that target sodium channels, azetukalner acts on Kv7.2/Kv7.3 potassium channels, which help regulate neuronal excitability. By enhancing the M-current, a potassium current that stabilizes the neuronal membrane potential, the drug is believed to reduce the excessive, synchronized electrical activity associated with seizures. Kv7.2/7.3 channels, located on neuronal cell bodies and axons, carry a potassium current called the M-current. The M-current stabilizes the membrane potential and dampens the hyperexcitable, synchronized firing associated with seizures. Azetukalner is believed to enhance this current by letting the channels open earlier and stay open longer, whereas most current antiseizure medications block sodium channels. As previously reported previously by Medscape Medical News, ezogabine, an earlier Kv7 channel opener, was approved by the FDA in 2011 for focal seizures. However, concerns about retinal abnormalities and skin discoloration prompted a boxed warning in 2013. The manufacturer ultimately withdrew the drug in 2017, citing limited use.The authors of the current study noted that ezogabine-associated discoloration was linked to the formation of pigmented molecules known as chromophoric dimers rather than to its action on Kv7 channels. Azetukalner is structurally distinct from ezogabine and does not form these dimers, French and colleagues noted.“We have very good, strong reasons to believe that the skin discoloration and the retinal issues came from a dimerization of the compound into crystals, and that does not happen with this compound,” said French, who also led a pivotal trial of ezogabine. “It is vanishingly unlikely that it would cause any of those problems.”Urinary retention, which also occurred with ezogabine, still happens occasionally with azetukalner but has resolved when the drug was stopped or the dose lowered. “You need to inform people that that’s a possibility, so that they can look out for it. But it doesn’t look like it’s a big safety issue,” French said.To evaluate the safety and efficacy of azetukalner as adjunctive treatment for adults with drug-resistant focal epilepsy, investigators conducted a phase 3 randomized, double-blind, placebo-controlled trial. The study was conducted from November 2022 to February 2026 at 138 sites in North America, Europe, South America, and the Asia Pacific region. It included 374 adults aged 18-81 years (mean age, 40 years; 50.8% women). Of these individuals, 81.8% were White and 3.7% were aged 65 years or older.Participants had lived with epilepsy for a mean of 25 years and experienced at least four focal seizures per month despite stable treatment with one to three ASMs. At baseline, they had a median of 12.75 seizures per month and had tried and stopped a median of five ASMs.Patients were randomly assigned to receive placebo or azetukalner at a dose of 15 mg or 25 mg once daily for 12 weeks. Treatment was administered with an evening meal to increase absorption. Some ASMs can speed up the breakdown of azetukalner by increasing the activity of the liver enzyme CYP3A4, so the investigators stratified randomization according to the use of these medications, which 68.7% of the study population were taking. The primary endpoint was the median percentage change from baseline in monthly seizure frequency. Key secondary endpoints included the proportion of participants with a reduction in seizure frequency of at least 50% and patient-reported improvement on the Patient Global Impression of Change scale.Overall, 88.8% of participants completed the 12-week double-blind period, including 78.2% of those receiving the 25-mg dose.Both azetukalner doses significantly reduced monthly seizure frequency compared with placebo (P < .001 for each). At least a 50% reduction in seizure frequency was achieved by 54.8% of participants receiving 25 mg (P < .001) and 37.6% receiving 15 mg (P = .003), compared with 20.8% receiving placebo.In the first week, seizure frequency decreased by a median of 45.2% on 25 mg vs 19.3% on placebo (P = .001). The 15-mg dose did not reach statistical significance at week 1. Over the full 12 weeks, 6.5% of participants receiving 25 mg were seizure-free, compared with 0.8% on placebo.The Seizure-Freedom CaveatHowever, French cautioned against directly comparing seizure freedom across trials. She noted that because azetukalner has a long half-life, drug exposure increases gradually even without titration, so “even if somebody had a seizure in day one or day two, they wouldn’t be counted as seizure free,” she said. Trials of cenobamate, another newer ASM, counted seizure freedom only after titration, making direct comparisons difficult, she added.French described one participant who had been on “ten, eleven, or twelve” ASMs, had undergone two brain resections, and had received deep brain and vagus nerve stimulators but still had daily seizures. “He went into the [azetukalner] study, and he became seizure free. And now, four years later, he is still seizure free,” she said.Adverse events led to discontinuation in 14.5% of participants receiving 25 mg compared with 4.8% receiving 15 mg and 3.2% receiving placebo. Dizziness was reported in 31.5% of participants in the 25-mg group compared with and 3.2% in the placebo group, while confusion occurred in 10.5% and 0.8%, respectively. Two participants receiving azetukalner experienced psychotic disorder events, both of which resolved. No deaths were reported.French noted that patients with epilepsy may be vulnerable to psychiatric disturbances when starting or stopping medications and that such effects may be dose related. Skin discoloration and retinal abnormalities, which had raised safety concerns with the earlier Kv7 channel opener ezogabine, were closely monitored during the trial and “no concerning events were observed.”“Not every person with epilepsy can see an epileptologist. There just is not enough of us,” said French. “We want a drug that is very effective, but easy for the broader community to use. And I’m hoping that this is that drug.”Promising Findings, but Questions RemainDespite the encouraging findings, questions remain about how well the results will translate into routine clinical practice. Lidia Moura, MD, PhD, MPH, director of population health at Massachusetts General Hospital and associate professor of neurology at Harvard Medical School in Boston, said the trial demonstrated short-term efficacy in a highly selected group of patients. Moura, who studies the safety of ASMs in older adults, was not involved in the research.“It does not yet tell us how the drug will perform in everyday practice, and that is what patients and clinicians ultimately care about,” she told Medscape Medical News.Moura cautioned against equating the number of ASMs with the treatment options available to individual patients. “I would gently push back on the idea that more than 30 approved medications means more than 30 options,” Moura said. “For any individual patient the real list is much shorter.”Moura agreed that the field needs new therapies but said expectations should be measured. “A new mechanism is welcome, but history tells us that a new mechanism alone has not changed outcomes at the population level,” she said.She also cautioned against interpreting azetukalner’s large treatment effect relative to placebo as evidence that it’s more effective than other newer ASMs. In addition, Moura raised questions about how episodes of confusion were assessed. “In a person with focal epilepsy, a new episode of confusion can also be a seizure, including a nonconvulsive seizure that looks different from the person’s usual events,” she said. Xenon Pharmaceuticals, which developed azetukalner and funded the trial, submitted a new drug application to the FDA in September. If approved, azetukalner would be the first Kv7 channel opener on the US market since ezogabine.Xenon Pharmaceuticals funded the story. French reported serving as a consultant for numerous pharmaceutical companies, including Xenon. Several coauthors are Xenon employees. Moura reported receiving fees from UCB and Pfizer and research support from the Centers for Disease Control and Prevention and the National Institutes of Health. She reported no financial relationships with Xenon.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.